查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
2012495

脐带血库市场：按库型、服务、应用和最终用户划分－2026-2032年全球预测

Umbilical Cord Blood Banking Market by Banking Model, Offerings, Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 187 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，脐带血库市场价值将达到 385.2 亿美元，到 2026 年将成长至 448.6 亿美元，到 2032 年将达到 1,194.4 亿美元，年复合成长率为 17.54%。

主要市场统计数据
基准年 2025 385.2亿美元
预计年份：2026年 448.6亿美元
预测年份 2032 1194.4亿美元
复合年增长率 (%) 17.54%

说明整体情况了不断发展的脐带血库产业，重点在于影响策略决策的临床期望、营运挑战和监管趋势。

脐带血库领域正处于临床需求、技术创新和不断变化的监管要求的交汇点。细胞处理和冷冻保存技术的进步重新激发了临床医生、研究人员和准父母的兴趣，而不断扩展的治疗应用也促进了产业与监管机构之间更深入的对话。因此，相关人员如今正面临一个生物资产长期储存与短期转化科学结合的复杂环境。

科学进步、营运标准化和不断发展的临床伙伴关係如何重塑整个产业的竞争重点和品质期望。

脐带血库产业正经历一场变革，这场变革的驱动力来自科学进步、处理技术的改进以及相关人员期望的不断变化。再生医学和细胞疗法的突破性进展正在拓展脐带血保存的临床意义，促使现有脐带血库和新参与企业重新评估其服务模式和价值提案。同时，自动化和标准化的活力检测提高了医疗专业人员和研究人员对品质标准的期望，并将竞争的焦点从价格转向了已证实的临床效用。

评估 2025 年贸易政策调整和关税如何重塑该产业的采购、供应链韧性和联合研究策略。

美国2025年实施的贸易政策措施和关税调整，给在全球脐带血库供应链中运作的组织带来了新的营运和战略压力。虽然采购专用低温冷冻库、实验室耗材和试剂通常依赖跨境供应商，但关税导致的投入成本增加迫使企业即时重新评估筹资策略。为此，许多相关人员加快了供应商多元化进程，并活性化讨论将关键製造能力外包到近岸地区的问题。

详细的細項分析揭示了每种银行模式、服务产品、临床应用和最终用户期望的不同需求，从而推动了策略差异化。

从银行模式的角度评估市场时，可以明显看出两类供应商的差异：一类专注于个人化储存服务，另一类则面向大众使用和器官移植支援。私人银行倾向于投资消费者意识宣传活动、长期客户维繫以及与家庭主导的获取途径相关的价值提案，而公共银行则优先考虑捐赠者招募、匹配系统以及与国家移植网络的合作。

美洲、欧洲、中东、非洲和亚太地区的区域趋势和监管细微差别决定了投资重点和战略伙伴关係。

区域趋势对法律规范、支付方态度以及脐带血库生态系的成熟度有显着影响。在美洲，成熟的私人脐带血库网络与公共登记系统并存，临床中心拥有良好的移植记录，从而支撑了对高品质脐带血的持续需求。区域监管机构正在逐步更新指导方针以应对细胞疗法，而私人企业则倾向于专注于消费者互动和产品差异化。

对竞争格局的评估表明，合作伙伴关係、技术差异化和产业重组正在重新定义企业策略和价值创造路径。

脐带血库产业的竞争格局由传统储存服务商、垂直整合的临床服务机构以及将创新处理和分析技术商业化的敏捷型Start-Ups组成。成熟的储存服务商通常利用其采集网路、客户关係和规模经济优势来进行长期储存业务，而新参与企业则倾向于专注于差异化的侦测能力、专有的活力检测方法或与药物研发公司的合作。

为领导者制定可操作的策略重点，重点在于产生临床证据、业务永续营运、策略伙伴关係和客户参与，以确保长期价值。

产业领导者应优先考虑平衡策略，既确保业务永续营运，也要提升临床可信度。首先，他们需要透过前瞻性註册研究和与临床医生合作，投资于实证医学证据的收集，以验证效用。这些工作应与完善的品质系统和透明的文件记录相协调，以促进与监管机构的沟通，并支援与支付方的对话。

一个强大的混合研究框架，结合专家访谈、监管审查和资料检验，为基于证据的策略建议提供支援。

本研究整合了对关键相关人员的访谈、监管和临床文献的回顾以及对工作实践的观察分析，以得出循证结论。关键要素包括与实验室主任、移植临床医生、器官捐赠协调员和监管事务专家进行结构化对话，以了解实际挑战和不断变化的期望。除了这些访谈外，研究还仔细审查记录程序创新和治疗结果的指导文件、临床试验註册资讯以及同行评审的研究。

本报告总结了品质、策略伙伴关係和供应链韧性如何决定哪些组织主导下一阶段的治疗和临床部署的结论。

科学进步、运作标准化和地缘政治压力相互交织，正为脐带血库生态系统带来意义深远的改变。目前，除了临床应用机会外，人们对脐带血库的可追溯性、品质和协作证据产生也提出了更高的期望。同时，供应链中断和关税趋势凸显了采购弹性和区域能力建构的重要性。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席体验长观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章：脐带血库市场：依血库模式划分

  • 私人的
  • 民众

第九章：脐带血库市场：依供应方式

  • 收藏
  • 过程
    • 细胞分离
    • 存活率检验
    • 产能下降
  • 发布
  • 保持

第十章：脐带血库市场：依应用领域划分

  • 血液疾病
    • 贫血
    • 白血病
    • 淋巴瘤
  • 免疫疾病
  • 代谢性疾病
  • 再生医学
  • 调查

第十一章：脐带血库市场：依最终用户划分

  • 诊断检测实验室
  • 医院和诊所
  • 研究机构

第十二章 脐带血库市场：依地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十三章：脐带血库市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十四章 脐带血库市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十五章：美国：脐带血库市场

第十六章 中国：脐带血库市场

第十七章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Cell Care Pty Ltd
  • Cord Blood Registry, LLC
  • Cryo-Cell International, Inc.
  • LifeCell International Private Limited
  • Macopharma SA
  • Smart Cells International
  • StemCyte, Inc.
  • Stemlife Berhad
  • ViaCord
  • ViaCord, LLC
Product Code: MRR-430D5F382283

The Umbilical Cord Blood Banking Market was valued at USD 38.52 billion in 2025 and is projected to grow to USD 44.86 billion in 2026, with a CAGR of 17.54%, reaching USD 119.44 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 38.52 billion
Estimated Year [2026] USD 44.86 billion
Forecast Year [2032] USD 119.44 billion
CAGR (%) 17.54%

Comprehensive orientation to the evolving cord blood banking landscape highlighting clinical promise, operational imperatives, and regulatory dynamics shaping strategic decisions

The umbilical cord blood banking field stands at the intersection of clinical promise, technological innovation, and evolving regulatory expectations. Advances in cell processing and cryopreservation have catalyzed renewed interest among clinicians, researchers, and prospective parents, while expanding therapeutic applications are driving deeper conversations between industry and regulators. As a result, stakeholders now navigate a landscape that blends long-term custody of biological assets with near-term translational science.

In practice, banking models and service offerings reflect distinct value propositions. Private banks emphasize individualized storage for potential autologous or family-directed use, while public banks focus on allogeneic availability for transplantation and research. Concurrently, improvements in laboratory automation, quality control, and viability assessment have compressed operational variances, enabling higher consistency across providers. Regulatory frameworks continue to shape permissible activities and commercialization pathways, and organizations that align clinical evidence generation with robust quality systems gain differentiated credibility.

This introduction frames the core dynamics that follow: structural shifts across the ecosystem, policy pressures from trade measures, segmentation-specific drivers, and practical recommendations for leaders who must translate scientific opportunity into reliable, compliant services. Through this lens, the remainder of the document outlines the forces that will most influence strategic choices over the near to medium term.

How scientific advances, operational standardization, and evolving clinical partnerships are reshaping competitive priorities and quality expectations across the industry

The landscape of cord blood banking is undergoing transformative shifts driven by converging scientific advances, improvements in processing technologies, and changing stakeholder expectations. Breakthroughs in regenerative medicine and cell therapy have expanded the clinical rationale for preserving cord blood, prompting both established banks and new entrants to revisit service models and value communications. At the same time, automation and standardized viability testing have raised the baseline quality that caregivers and researchers now expect, shifting competition away from price toward demonstrated clinical utility.

Moreover, partnerships between banking organizations and biotechnology firms are accelerating translational pathways. These collaborations foster shared investment in protocols that support novel applications, including immunotherapies and regenerative indications. Concurrently, payers and health systems are beginning to evaluate long-term outcomes, which will influence reimbursement conversations and patient demand. Regulatory bodies are also adapting oversight frameworks to accommodate emerging cell-based therapies, creating new compliance requirements that necessitate proactive quality and documentation strategies.

Taken together, these factors are reshaping strategic priorities across the sector. Organizations that invest in evidence generation, strengthen traceability and cold chain governance, and cultivate clinical partnerships will navigate the transition more successfully, while those that delay integration of new technologies and regulatory alignment may face competitive and compliance risks.

Assessment of how 2025 trade policy adjustments and tariffs reshaped procurement, supply chain resilience, and collaborative research strategies within the sector

The introduction of trade policy measures and tariff adjustments by the United States in 2025 introduced a new set of operational and strategic pressures for organizations active in global supply chains supporting cord blood banking. Sourcing of specialized cryogenic freezers, laboratory consumables, and reagents often relies on cross-border suppliers, and tariff-driven input cost increases necessitated immediate reassessment of procurement strategies. In response, many stakeholders accelerated supplier diversification and intensified conversations about nearshoring of critical manufacturing capacity.

Beyond procurement, tariffs influenced collaborative research arrangements. Cross-border clinical collaborations and reagent sharing require clear contractual terms to manage cost volatility. Institutions adapted by revising contractual risk allocations and by establishing inventory buffers for time-sensitive reagents. Additionally, the heightened cost visibility prompted innovation in resource utilization, such as optimizing storage formats and improving volume reduction techniques to reduce consumable consumption per specimen.

From a strategic perspective, the tariff environment catalyzed stronger emphasis on supply chain transparency and resilience. Organizations that had previously underinvested in supplier qualification and contingency planning found themselves revisiting those priorities. Conversely, those that leveraged strategic procurement, long-term supplier agreements, and incremental investments in domestic capabilities minimized disruption and maintained continuity of clinical and research activities.

Deep segmentation analysis revealing distinct requirements across banking models, service offerings, clinical applications, and end-user expectations that drive strategic differentiation

When evaluating the market through the lens of banking model, a clear dichotomy emerges between providers focused on individualized custodial services and those oriented toward public availability and transplantation support. Private banks tend to invest in consumer-facing education, long-term customer retention, and value propositions tied to family-directed access, while public banks prioritize donor recruitment, matching systems, and integration with national transplant networks.

Examining offerings reveals discrete operational domains: collection processes that ensure sterile, timely retrieval at birth; processing functions that include cell separation, viability testing, and volume reduction to prepare units for cryostorage; release procedures that govern clinical dispatch for transplantation or research; and long-term storage systems that maintain sample integrity under rigorous traceability and temperature control. Innovations in any of these stages can materially affect downstream usability and cost structures.

Application-based segmentation highlights clinical and scientific priorities. Blood disorders such as anemia, leukemia, and lymphoma remain core therapeutic targets for cord blood transplantation, while immune disorders and metabolic conditions continue to drive research interest. Regenerative medicine and research applications expand the potential utility of stored units, requiring additional data on potency and longer-term outcomes to support wider adoption.

Finally, end users-including diagnostic laboratories, hospitals and clinics, and research institutes-engage with banks under different time horizons and quality expectations. Diagnostic laboratories often require validated sample processing and strict chain-of-custody documentation, whereas hospitals and clinics demand operational excellence at the point of collection and seamless clinical integration. Research institutes prioritize accessibility and standardized metadata to enable reproducible studies. Understanding these nuanced needs across segmentation axes informs tailored service design and contract structures.

Regional dynamics and regulatory nuances across the Americas, Europe-Middle East-Africa, and Asia-Pacific that determine investment priorities and strategic partnerships

Regional dynamics exert powerful influence on regulatory frameworks, payer attitudes, and the maturity of cord blood banking ecosystems. In the Americas, established private banking networks coexist with public registries, and clinical centers maintain strong transplantation experience that supports sustained demand for high-quality units. Regional regulatory bodies have incrementally updated guidance to accommodate cell therapies, and commercial players often emphasize consumer engagement and product differentiation.

In Europe, the Middle East & Africa region, regulatory harmonization efforts and national tissue directives shape operational requirements. Public banking infrastructure and national registries play a prominent role in certain countries, while cross-border cooperation supports transplantation matching. Regulatory nuance across jurisdictions requires banks to invest in multi-jurisdictional compliance programs and localized clinical partnerships to ensure access to varied patient populations.

Across the Asia-Pacific region, rapid adoption of novel therapies and investment in biotechnology infrastructure drive demand for both private and public banking services. Growth in clinical trials and translational research has created opportunities for collaborative models between banks and therapeutic developers. However, heterogeneity in regulatory maturity and varying reimbursement landscapes necessitate localized strategies that account for cultural, clinical, and policy differences. These regional distinctions inform where to prioritize investments in infrastructure, clinical outreach, and compliance capabilities.

Competitive landscape assessment showing how alliances, technological differentiation, and consolidation are redefining company strategies and value creation pathways

Competitive dynamics in the cord blood banking sector reflect a mix of legacy custodial providers, vertically integrated clinical service organizations, and nimble startups that commercialize novel processing and analytics technologies. Established custodial providers typically leverage scale in collection networks, customer relationships, and long-term storage operations, while newer entrants often focus on differentiated laboratory capabilities, proprietary viability assays, or partnerships with therapeutic developers.

Strategic alliances between banks and biotechnology companies have become increasingly prevalent as developers seek reliable, high-quality source material for clinical programs. These alliances frequently include co-investment in processing protocols, validation studies, and data sharing agreements that accelerate translational timelines. Similarly, technology vendors supplying automated processing platforms and advanced cryogenic hardware have created opportunities for banks to raise quality standards and reduce per-unit variability.

Mergers and acquisitions continue to influence the competitive landscape, with consolidation enabling scale economies in storage and compliance while also driving integration of clinical and research services. At the same time, institutional investors and healthcare systems are exploring joint ventures and captive banking solutions to secure access to qualified donor material for internal therapeutic pipelines. In aggregate, these company-level strategies reflect a market where differentiation increasingly rests on evidence generation, supply chain reliability, and the capacity to support clinical development partners.

Actionable strategic priorities for leaders focused on clinical evidence generation, operational resilience, strategic partnerships, and customer engagement to secure long-term value

Industry leaders should prioritize a balanced approach that strengthens clinical credibility while building operational resilience. First, invest in evidence generation through prospective registries and clinician partnerships to substantiate clinical utility across target indications. Align these efforts with robust quality systems and transparent documentation to ease regulatory interactions and support payer conversations.

Second, enhance supply chain resilience by diversifying vendors for critical equipment and consumables, negotiating multi-year agreements where feasible, and exploring regional manufacturing or procurement hubs to mitigate tariff-driven volatility. Simultaneously, adopt laboratory automation and standardized viability testing to reduce operational variability and improve unit usability for translational programs.

Third, pursue strategic collaborations with therapeutic developers and research institutes. Co-development agreements and material access arrangements can create new revenue streams and accelerate the clinical validation of cord blood-derived applications. Finally, strengthen customer-facing capabilities through clearer education, post-storage engagement, and digital portals that simplify long-term custody decisions and enable lifecycle monetization opportunities. Taken together, these actions will position organizations to capture clinical opportunities while managing regulatory and commercial risk.

Robust mixed-methods research framework combining expert interviews, regulatory review, and data triangulation to underpin evidence-based strategic recommendations

This research synthesizes primary stakeholder interviews, regulatory and clinical literature review, and observational analysis of operational practices to construct evidence-based conclusions. Primary engagement included structured conversations with laboratory directors, transplant clinicians, procurement specialists, and regulatory affairs professionals to capture practical challenges and evolving expectations. These interviews were complemented by careful review of guidance documents, clinical trial registries, and peer-reviewed studies that document procedural innovations and therapeutic outcomes.

Secondary research incorporated industry publications, technology vendor specifications, and publicly available policy updates to contextualize operational trends within broader trade and regulatory developments. Data triangulation ensured consistency across sources, with discrepant findings subjected to follow-up inquiries or cross-verification through alternate data channels. Quality assurance processes included expert peer review and scenario analysis to identify plausible responses to policy shifts and technological adoption curves.

Methodologically, the study emphasized qualitative depth over speculative quantitative projections. That emphasis enables readers to understand causal relationships, operational levers, and the pragmatic steps required to translate scientific promise into dependable services. Transparency in source attribution and methodological limitations accompanies all major assertions to support confident decision-making.

Conclusion summarizing how quality, strategic partnerships, and supply chain resilience determine which organizations will lead the next phase of therapeutic and clinical adoption

The convergence of scientific advances, operational standardization, and geopolitical pressures is reshaping the cord blood banking ecosystem in meaningful ways. Clinical opportunity now coexists with increased expectations for traceability, quality, and collaborative evidence generation. At the same time, supply chain disruptions and tariff dynamics have highlighted the importance of procurement agility and regional capacity building.

Organizations that align laboratory excellence with proactive regulatory engagement and strategic partnerships will secure competitive advantage. Investing in validated processing protocols, automated viability testing, and durable clinical relationships creates a foundation for long-term relevance. Conversely, those that delay integrating new technologies or fail to shore up supply chain resilience risk operational discontinuities and diminished clinical credibility.

In closing, the sector's trajectory favors actors who view cord blood banking not merely as a custodial service, but as an integral partner in translational science. By emphasizing quality, collaboration, and adaptability, leaders can unlock broader clinical applications while safeguarding the integrity of stored biological assets.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Umbilical Cord Blood Banking Market, by Banking Model

  • 8.1. Private
  • 8.2. Public

9. Umbilical Cord Blood Banking Market, by Offerings

  • 9.1. Collection
  • 9.2. Processing
    • 9.2.1. Cell Separation
    • 9.2.2. Viability Testing
    • 9.2.3. Volume Reduction
  • 9.3. Release
  • 9.4. Storage

10. Umbilical Cord Blood Banking Market, by Application

  • 10.1. Blood Disorders
    • 10.1.1. Anemia
    • 10.1.2. Leukemia
    • 10.1.3. Lymphoma
  • 10.2. Immune Disorders
  • 10.3. Metabolic Disorders
  • 10.4. Regenerative Medicine
  • 10.5. Research

11. Umbilical Cord Blood Banking Market, by End User

  • 11.1. Diagnostic Laboratories
  • 11.2. Hospitals And Clinics
  • 11.3. Research Institutes

12. Umbilical Cord Blood Banking Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Umbilical Cord Blood Banking Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Umbilical Cord Blood Banking Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Umbilical Cord Blood Banking Market

16. China Umbilical Cord Blood Banking Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Cell Care Pty Ltd
  • 17.6. Cord Blood Registry, LLC
  • 17.7. Cryo-Cell International, Inc.
  • 17.8. LifeCell International Private Limited
  • 17.9. Macopharma S.A.
  • 17.10. Smart Cells International
  • 17.11. StemCyte, Inc.
  • 17.12. Stemlife Berhad
  • 17.13. ViaCord
  • 17.14. ViaCord, LLC

LIST OF FIGURES

  • FIGURE 1. GLOBAL UMBILICAL CORD BLOOD BANKING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL UMBILICAL CORD BLOOD BANKING MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL UMBILICAL CORD BLOOD BANKING MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY BANKING MODEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY OFFERINGS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES UMBILICAL CORD BLOOD BANKING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA UMBILICAL CORD BLOOD BANKING MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL UMBILICAL CORD BLOOD BANKING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY BANKING MODEL, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY PRIVATE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY PRIVATE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY PRIVATE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY PUBLIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY PUBLIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY PUBLIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY OFFERINGS, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY COLLECTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY COLLECTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY COLLECTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY PROCESSING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY PROCESSING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY PROCESSING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY PROCESSING, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY CELL SEPARATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY CELL SEPARATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY CELL SEPARATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY VIABILITY TESTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY VIABILITY TESTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY VIABILITY TESTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY VOLUME REDUCTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY VOLUME REDUCTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY VOLUME REDUCTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY RELEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY RELEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY RELEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY STORAGE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY STORAGE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY STORAGE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY BLOOD DISORDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY BLOOD DISORDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY BLOOD DISORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY BLOOD DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY ANEMIA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY ANEMIA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY ANEMIA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY LEUKEMIA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY LEUKEMIA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY LEUKEMIA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY LYMPHOMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY LYMPHOMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY LYMPHOMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY IMMUNE DISORDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY IMMUNE DISORDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY IMMUNE DISORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY METABOLIC DISORDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY METABOLIC DISORDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY METABOLIC DISORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY REGENERATIVE MEDICINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY REGENERATIVE MEDICINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY REGENERATIVE MEDICINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY RESEARCH, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY RESEARCH, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY RESEARCH, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY HOSPITALS AND CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY HOSPITALS AND CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY HOSPITALS AND CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. AMERICAS UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 70. AMERICAS UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY BANKING MODEL, 2018-2032 (USD MILLION)
  • TABLE 71. AMERICAS UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY OFFERINGS, 2018-2032 (USD MILLION)
  • TABLE 72. AMERICAS UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY PROCESSING, 2018-2032 (USD MILLION)
  • TABLE 73. AMERICAS UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 74. AMERICAS UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY BLOOD DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 75. AMERICAS UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 76. NORTH AMERICA UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. NORTH AMERICA UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY BANKING MODEL, 2018-2032 (USD MILLION)
  • TABLE 78. NORTH AMERICA UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY OFFERINGS, 2018-2032 (USD MILLION)
  • TABLE 79. NORTH AMERICA UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY PROCESSING, 2018-2032 (USD MILLION)
  • TABLE 80. NORTH AMERICA UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 81. NORTH AMERICA UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY BLOOD DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 82. NORTH AMERICA UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 83. LATIN AMERICA UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. LATIN AMERICA UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY BANKING MODEL, 2018-2032 (USD MILLION)
  • TABLE 85. LATIN AMERICA UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY OFFERINGS, 2018-2032 (USD MILLION)
  • TABLE 86. LATIN AMERICA UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY PROCESSING, 2018-2032 (USD MILLION)
  • TABLE 87. LATIN AMERICA UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 88. LATIN AMERICA UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY BLOOD DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 89. LATIN AMERICA UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 90. EUROPE, MIDDLE EAST & AFRICA UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 91. EUROPE, MIDDLE EAST & AFRICA UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY BANKING MODEL, 2018-2032 (USD MILLION)
  • TABLE 92. EUROPE, MIDDLE EAST & AFRICA UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY OFFERINGS, 2018-2032 (USD MILLION)
  • TABLE 93. EUROPE, MIDDLE EAST & AFRICA UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY PROCESSING, 2018-2032 (USD MILLION)
  • TABLE 94. EUROPE, MIDDLE EAST & AFRICA UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 95. EUROPE, MIDDLE EAST & AFRICA UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY BLOOD DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 96. EUROPE, MIDDLE EAST & AFRICA UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 97. EUROPE UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 98. EUROPE UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY BANKING MODEL, 2018-2032 (USD MILLION)
  • TABLE 99. EUROPE UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY OFFERINGS, 2018-2032 (USD MILLION)
  • TABLE 100. EUROPE UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY PROCESSING, 2018-2032 (USD MILLION)
  • TABLE 101. EUROPE UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 102. EUROPE UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY BLOOD DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 103. EUROPE UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 104. MIDDLE EAST UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 105. MIDDLE EAST UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY BANKING MODEL, 2018-2032 (USD MILLION)
  • TABLE 106. MIDDLE EAST UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY OFFERINGS, 2018-2032 (USD MILLION)
  • TABLE 107. MIDDLE EAST UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY PROCESSING, 2018-2032 (USD MILLION)
  • TABLE 108. MIDDLE EAST UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 109. MIDDLE EAST UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY BLOOD DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 110. MIDDLE EAST UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 111. AFRICA UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 112. AFRICA UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY BANKING MODEL, 2018-2032 (USD MILLION)
  • TABLE 113. AFRICA UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY OFFERINGS, 2018-2032 (USD MILLION)
  • TABLE 114. AFRICA UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY PROCESSING, 2018-2032 (USD MILLION)
  • TABLE 115. AFRICA UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 116. AFRICA UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY BLOOD DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 117. AFRICA UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 118. ASIA-PACIFIC UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 119. ASIA-PACIFIC UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY BANKING MODEL, 2018-2032 (USD MILLION)
  • TABLE 120. ASIA-PACIFIC UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY OFFERINGS, 2018-2032 (USD MILLION)
  • TABLE 121. ASIA-PACIFIC UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY PROCESSING, 2018-2032 (USD MILLION)
  • TABLE 122. ASIA-PACIFIC UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 123. ASIA-PACIFIC UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY BLOOD DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 124. ASIA-PACIFIC UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 126. ASEAN UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 127. ASEAN UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY BANKING MODEL, 2018-2032 (USD MILLION)
  • TABLE 128. ASEAN UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY OFFERINGS, 2018-2032 (USD MILLION)
  • TABLE 129. ASEAN UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY PROCESSING, 2018-2032 (USD MILLION)
  • TABLE 130. ASEAN UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 131. ASEAN UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY BLOOD DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 132. ASEAN UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 133. GCC UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 134. GCC UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY BANKING MODEL, 2018-2032 (USD MILLION)
  • TABLE 135. GCC UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY OFFERINGS, 2018-2032 (USD MILLION)
  • TABLE 136. GCC UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY PROCESSING, 2018-2032 (USD MILLION)
  • TABLE 137. GCC UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 138. GCC UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY BLOOD DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 139. GCC UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 140. EUROPEAN UNION UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 141. EUROPEAN UNION UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY BANKING MODEL, 2018-2032 (USD MILLION)
  • TABLE 142. EUROPEAN UNION UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY OFFERINGS, 2018-2032 (USD MILLION)
  • TABLE 143. EUROPEAN UNION UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY PROCESSING, 2018-2032 (USD MILLION)
  • TABLE 144. EUROPEAN UNION UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 145. EUROPEAN UNION UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY BLOOD DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 146. EUROPEAN UNION UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 147. BRICS UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 148. BRICS UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY BANKING MODEL, 2018-2032 (USD MILLION)
  • TABLE 149. BRICS UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY OFFERINGS, 2018-2032 (USD MILLION)
  • TABLE 150. BRICS UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY PROCESSING, 2018-2032 (USD MILLION)
  • TABLE 151. BRICS UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 152. BRICS UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY BLOOD DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 153. BRICS UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 154. G7 UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 155. G7 UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY BANKING MODEL, 2018-2032 (USD MILLION)
  • TABLE 156. G7 UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY OFFERINGS, 2018-2032 (USD MILLION)
  • TABLE 157. G7 UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY PROCESSING, 2018-2032 (USD MILLION)
  • TABLE 158. G7 UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 159. G7 UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY BLOOD DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 160. G7 UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 161. NATO UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 162. NATO UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY BANKING MODEL, 2018-2032 (USD MILLION)
  • TABLE 163. NATO UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY OFFERINGS, 2018-2032 (USD MILLION)
  • TABLE 164. NATO UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY PROCESSING, 2018-2032 (USD MILLION)
  • TABLE 165. NATO UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 166. NATO UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY BLOOD DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 167. NATO UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 168. GLOBAL UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 169. UNITED STATES UMBILICAL CORD BLOOD BANKING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 170. UNITED STATES UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY BANKING MODEL, 2018-2032 (USD MILLION)
  • TABLE 171. UNITED STATES UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY OFFERINGS, 2018-2032 (USD MILLION)
  • TABLE 172. UNITED STATES UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY PROCESSING, 2018-2032 (USD MILLION)
  • TABLE 173. UNITED STATES UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 174. UNITED STATES UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY BLOOD DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 175. UNITED STATES UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 176. CHINA UMBILICAL CORD BLOOD BANKING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 177. CHINA UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY BANKING MODEL, 2018-2032 (USD MILLION)
  • TABLE 178. CHINA UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY OFFERINGS, 2018-2032 (USD MILLION)
  • TABLE 179. CHINA UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY PROCESSING, 2018-2032 (USD MILLION)
  • TABLE 180. CHINA UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 181. CHINA UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY BLOOD DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 182. CHINA UMBILICAL CORD BLOOD BANKING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)